The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01098539




Registration number
NCT01098539
Ethics application status
Date submitted
1/04/2010
Date registered
2/04/2010
Date last updated
28/02/2017

Titles & IDs
Public title
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Scientific title
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment
Secondary ID [1] 0 0
114130
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - albiglutide
Treatment: Drugs - sitagliptin

Active Comparator: albiglutide - albiglutide weekly subcutaneous injection + sitagliptin matching placebo

Active Comparator: sitagliptin - albiglutide matching placebo + sitagliptin


Other interventions: albiglutide
albiglutide weekly subcutaneous injection + sitagliptin matching placebo

Treatment: Drugs: sitagliptin
albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 - HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 26 minus the value at Baseline. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (<65 years versus >=65 years) as factors and Baseline HbA1c as a continuous covariate. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Timepoint [1] 0 0
Baseline; Week 26
Secondary outcome [1] 0 0
Mean Change From Baseline in HbA1c at Weeks 4, 8, 12, 16, and 20: LOCF - HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Timepoint [1] 0 0
Baseline; Weeks 4, 8, 12, 16, and 20
Secondary outcome [2] 0 0
Mean Change From Baseline in HbA1c at Weeks 4, 8, 12, 16, 20, 26, 36, 48, and Week 52: Observed Cases - HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the post-Baseline value minus the Baseline value. The Observed Cases (OC) method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Timepoint [2] 0 0
Baseline; Weeks 4, 8, 12, 16, 20, 26, 36, 48, and 52
Secondary outcome [3] 0 0
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is define as the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week. Based on ANCOVA: Change = treatment + Baseline FPG + renal impairment + prior myocardial infarction history + age category + region.
Timepoint [3] 0 0
Baseline; Week 26
Secondary outcome [4] 0 0
Mean Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, and 26: LOCF - The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Timepoint [4] 0 0
Baseline; Weeks 4, 8, 12, 16, 20, and 26
Secondary outcome [5] 0 0
Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1, 2, 3, 4, 8, 12, 16, 20, 26, 36, 48, and Week 52: OC - The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is defined as the last non-missing value prior to treatment. Change from Baseline in FBG was calculated as the post-Baseline value minus the Baseline value. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing. Participants were analyzed in a particular treatment week if they had received at least one dose in that treatment week.
Timepoint [5] 0 0
Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 26, 36, 48, Week 52
Secondary outcome [6] 0 0
Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5% and <7.0% at Week 26: LOCF - The number of participants who acheieved the HbA1c treatment goal (i.e., the number of participants who achieved HbA1c <7% and <6.5% at Week 26) was assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Timepoint [6] 0 0
Week 26
Secondary outcome [7] 0 0
Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of >=1.0%, >=1.5%, and >=2.0% at Week 26: LOCF - The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of >=1.0%, >=1.5%, and >=2.0% at Week 26 were assessed. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurement. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Timepoint [7] 0 0
Week 26
Secondary outcome [8] 0 0
Number of Participants Who Achieved a Clinically Meaningful HbA1c Response Level of <6.5% and <7.0% at Week 52: OC - The number of participants who acheieved the HbA1c treatment goal (i.e., number of participants who achieved HbA1c <7% and <6.5% at Week 26) was assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Timepoint [8] 0 0
Week 52
Secondary outcome [9] 0 0
Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of >=1.0%, >=1.5%, and >=2.0% at Week 52: OC - The number of participants who a clinically meaningful improvement from Baseline in the HbA1c response level of >=1.0%, >=1.5%, and >=2.0% at Week 52 assessed. The OC method (no imputation of missing data) was used. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
Timepoint [9] 0 0
Week 52
Secondary outcome [10] 0 0
Number of Participants With the Indicated Time to Hyperglycemic Rescue Through Week 52 - Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value >=280 milligrams per deciliter (mg/dL); for the >Week 4 and <Week 12 visits, a single FPG value >=250 mg/dL and previous titration for >=4 weeks; for the >=Week 12 and <Week 26 visits, HbA1c >=8.5% and a <=0.5% reduction from Baseline and previous titration for >=4 weeks; for the >=Week 26 and <Week 48 visits, HbA1c >=8.5% and previous titration for >=4 weeks; for the >=Week 48 and <Week 52 visits, HbA1c >=8.0% and previous titration for >=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue.
Timepoint [10] 0 0
Week 2 to Week 52
Secondary outcome [11] 0 0
Time to Hyperglycemic Rescue Through Week 52 - Hyperglycemic rescue was defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days and analyzed by the central laboratory: for the Week 2 to Week 4 visit, a single FPG value >=280 milligrams per deciliter (mg/dL); for the >Week 4 and <Week 12 visits, a single FPG value >=250 mg/dL and previous titration for >=4 weeks; for the >=Week 12 and <Week 26 visits, HbA1c >=8.5% and a <=0.5% reduction from Baseline and previous titration for >=4 weeks; for the >=Week 26 and <Week 48 visits, HbA1c >=8.5% and previous titration for >=4 weeks; for the >=Week 48 and <Week 52 visits, HbA1c >=8.0% and previous titration for >=4 weeks. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue. This time is divided by 7 to express the result in weeks.
Timepoint [11] 0 0
Week 2 to Week 52
Secondary outcome [12] 0 0
Change From Baseline in Body Weight at Week 26: LOCF - Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values. Based on ANCOVA: Change = treatment + Baseline weight + renal impairment + prior myocardial infarction history + age category + region.
Timepoint [12] 0 0
Baseline; Week 26
Secondary outcome [13] 0 0
Change From Baseline in Body Weight Through Week 26: LOCF - Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used the LOCF method for missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue werre treated as missing and were replaced with pre-rescue values.
Timepoint [13] 0 0
Baseline; Week 1, Week 2 , Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 26
Secondary outcome [14] 0 0
Change From Baseline in Body Weight Through Week 52: OC - Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The Baseline weight value is defined as the last non-missing value prior to treatment. This analysis used observed weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.
Timepoint [14] 0 0
Baseline; Week 1, Week 2 , Week 3, Week 4, Week 8, Week 12, Week 16, Week 20, Week 26, Week 36, Week 48, and Week 52
Secondary outcome [15] 0 0
Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16 - Sparse population pharmacokinetic (PK) data were collected for population PK and PK/pharmacodynamic (PD) analyses. Participants (par.) who received albiglutide were initiated on a 30 mg weekly dosing regimen. Beginning at Week 4, uptitration of albiglutide was allowed based on glycemic parameters. As such, albiglutide plasma conc. achieved at each sampling time represent a mixed population of par. who received either 30 mg or 50 mg weekly for various durations. The PK and PK/PD of albiglutide were characterized using a population modeling approach. Mean albiglutide plasma conc. observed at Weeks 8 and 16 are presented. Par. came to the clinic at Weeks 8 and 16 without taking albiglutide/matching placebo. The pre-dose PK sample was taken immediately prior to dosing. The Week 8 post-dose sample was taken between Weeks 8 and 10, >=2 days after a dose of medication. The Week 16 post-dose PK sample was taken any time between Weeks 16 and 20, >=2 days after the previous dose of albiglutide.
Timepoint [15] 0 0
Week 8 Pre-dose (immediately prior to dose), Week 8 Post-dose (at least 2 days after a dose of medication), Week 16 Pre-dose (immediately prior to dose), and Week 16 Post-dose (at least 2 days after previous dose of albiglutide)

Eligibility
Key inclusion criteria
- Renally impaired with a historical diagnosis of type 2 diabetes mellitus and is
experiencing inadequate glycemic control on their current regime of diet and exercise
or their antidiabetic therapy of metformin, TZD, SU, or any combination of these oral
antidiabetic medications

- BMI >/=20 kg/m2 and </=45 kg/m2

- Fasting C-peptide >/=0.8 ng/mL (>/=0.26 nmol/L)

- HbA1c between 7.0% and 10.0%, inclusive.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of cancer

- History of treated diabetic gastroparesis

- Current biliary disease or history of pancreatitis

- History of significant gastrointestinal surgery

- Recent clinically significant cardiovascular and/or cerebrovascular disease

- History of human immunodeficiency virus infection

- Abnormal liver function or acute symptomatic infection with hepatitis B or hepatitis C

- Female subject is pregnant (confirmed by laboratory testing), lactating, or <6 weeks
postpartum

- Known allergy to any GLP 1 analogue, sitagliptin, other study medications' excipients,
excipients of albiglutide, or Baker's yeast

- Receipt of any investigational drug or sitagliptin within the 30 days or 5 half lives,
whichever is longer, before Screening or a history of receipt of an investigational
antidiabetic drug within the 3 months before randomization or receipt of albiglutide
in previous studies

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Garran
Recruitment hospital [2] 0 0
GSK Investigational Site - Camperdown
Recruitment hospital [3] 0 0
GSK Investigational Site - Auchenflower
Recruitment hospital [4] 0 0
GSK Investigational Site - Caboolture
Recruitment hospital [5] 0 0
GSK Investigational Site - Herston
Recruitment hospital [6] 0 0
GSK Investigational Site - Kippa Ring
Recruitment hospital [7] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [8] 0 0
GSK Investigational Site - Clayton
Recruitment hospital [9] 0 0
GSK Investigational Site - Heidelberg
Recruitment hospital [10] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [11] 0 0
GSK Investigational Site - Parkville
Recruitment hospital [12] 0 0
GSK Investigational Site - Fremantle
Recruitment postcode(s) [1] 0 0
2606 - Garran
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
4066 - Auchenflower
Recruitment postcode(s) [4] 0 0
4510 - Caboolture
Recruitment postcode(s) [5] 0 0
4029 - Herston
Recruitment postcode(s) [6] 0 0
4021 - Kippa Ring
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3168 - Clayton
Recruitment postcode(s) [9] 0 0
3081 - Heidelberg
Recruitment postcode(s) [10] 0 0
3135 - Melbourne
Recruitment postcode(s) [11] 0 0
3050 - Parkville
Recruitment postcode(s) [12] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Vermont
Country [29] 0 0
United States of America
State/province [29] 0 0
Virginia
Country [30] 0 0
United States of America
State/province [30] 0 0
Washington
Country [31] 0 0
Brazil
State/province [31] 0 0
Rio Grande Do Sul
Country [32] 0 0
Brazil
State/province [32] 0 0
Brasília
Country [33] 0 0
Brazil
State/province [33] 0 0
Mogi das Cruzes
Country [34] 0 0
Brazil
State/province [34] 0 0
São Paulo
Country [35] 0 0
Colombia
State/province [35] 0 0
Barrangquilla
Country [36] 0 0
Colombia
State/province [36] 0 0
Bogota
Country [37] 0 0
Colombia
State/province [37] 0 0
Floridablanca-Santander
Country [38] 0 0
Germany
State/province [38] 0 0
Hessen
Country [39] 0 0
Germany
State/province [39] 0 0
Niedersachsen
Country [40] 0 0
Germany
State/province [40] 0 0
Rheinland-Pfalz
Country [41] 0 0
Germany
State/province [41] 0 0
Sachsen
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
India
State/province [43] 0 0
Ahmedabad
Country [44] 0 0
India
State/province [44] 0 0
Bangalore
Country [45] 0 0
India
State/province [45] 0 0
Belgaum,
Country [46] 0 0
India
State/province [46] 0 0
Belgaum
Country [47] 0 0
India
State/province [47] 0 0
Chennai
Country [48] 0 0
India
State/province [48] 0 0
Lucknow
Country [49] 0 0
India
State/province [49] 0 0
Manipal
Country [50] 0 0
India
State/province [50] 0 0
Mumbai
Country [51] 0 0
India
State/province [51] 0 0
Nasik
Country [52] 0 0
Israel
State/province [52] 0 0
Ashkelon
Country [53] 0 0
Israel
State/province [53] 0 0
Beer-Sheva
Country [54] 0 0
Israel
State/province [54] 0 0
Haifa
Country [55] 0 0
Israel
State/province [55] 0 0
Holon
Country [56] 0 0
Israel
State/province [56] 0 0
Kfar Saba
Country [57] 0 0
Israel
State/province [57] 0 0
Safed
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seongnam-si
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seoul
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Suwon, Kyonggi-do
Country [61] 0 0
Peru
State/province [61] 0 0
Lima
Country [62] 0 0
Peru
State/province [62] 0 0
Arequipa
Country [63] 0 0
Peru
State/province [63] 0 0
Ica
Country [64] 0 0
Peru
State/province [64] 0 0
Piura
Country [65] 0 0
Peru
State/province [65] 0 0
Trujillo
Country [66] 0 0
Philippines
State/province [66] 0 0
Cebu City
Country [67] 0 0
Philippines
State/province [67] 0 0
Iloilo City
Country [68] 0 0
Philippines
State/province [68] 0 0
Makati City
Country [69] 0 0
Philippines
State/province [69] 0 0
Pasay
Country [70] 0 0
Philippines
State/province [70] 0 0
Tagbilaran City
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Nizhniy Novgorod
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Saratov
Country [73] 0 0
Russian Federation
State/province [73] 0 0
St'Petersburg
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Yaroslavl
Country [75] 0 0
South Africa
State/province [75] 0 0
Eastern Cape
Country [76] 0 0
South Africa
State/province [76] 0 0
Gauteng
Country [77] 0 0
South Africa
State/province [77] 0 0
KwaZulu- Natal
Country [78] 0 0
South Africa
State/province [78] 0 0
Houghton
Country [79] 0 0
South Africa
State/province [79] 0 0
Pretoria
Country [80] 0 0
South Africa
State/province [80] 0 0
Somerset West
Country [81] 0 0
South Africa
State/province [81] 0 0
Tygerberg
Country [82] 0 0
Spain
State/province [82] 0 0
Alicante
Country [83] 0 0
Spain
State/province [83] 0 0
La Coruña
Country [84] 0 0
Spain
State/province [84] 0 0
Málaga
Country [85] 0 0
Spain
State/province [85] 0 0
Palma de Mallorca
Country [86] 0 0
Spain
State/province [86] 0 0
Santiago de Compostela
Country [87] 0 0
Spain
State/province [87] 0 0
Sevilla
Country [88] 0 0
Spain
State/province [88] 0 0
Torrevieja (Alicante)
Country [89] 0 0
Taiwan
State/province [89] 0 0
Kaohsiung
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taichung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Tainan
Country [92] 0 0
United Kingdom
State/province [92] 0 0
West Midlands
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Birmingham
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Hertfordshire
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Hull
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Liverpool
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Livingston
Country [98] 0 0
United Kingdom
State/province [98] 0 0
London
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Plymouth
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a
weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired
with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately
controlled on their current regimen of diet and exercise or their antidiabetic therapy of
metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic
medications will be recruited into the study.
Trial website
https://clinicaltrials.gov/show/NCT01098539
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications